首页> Targeted oncology> Circulating Tumor DNA in Advanced EGFRex20+ NSCLC: Concordance with Tissue Biopsy, Monitoring of Response, and Resistance to High-Dose Osimertinib.

Circulating Tumor DNA in Advanced EGFRex20+ NSCLC: Concordance with Tissue Biopsy, Monitoring of Response, and Resistance to High-Dose Osimertinib.

导出 OA

翻译打印收藏纠错

第一作者： Fenneke,Zwierenga

第一单位： Department of Pulmonary Medicine, University of Groningen, University Medical Center Groningen, HPC AA11, Postbus 30.001, 9700RB, Groningen, The Netherlands.

作者： Fenneke,Zwierenga ^[1] ; M Benthe,Muntinghe-Wagenaar ^[2] ; Pim,Rozendal ^[3] ; Adrianus J,de Langen ^[4] ; Lizza E L,Hendriks ^[5] ; Michel,van den Heuvel ^[6] ; Cor,van der Leest ^[7] ; Sayed M S,Hashemi ^[8] ; Paul,van der Leest ^[3] ; T Jeroen N,Hiltermann ^[3] ; Ed,Schuuring ^[3] ; Anthonie J,van der Wekken ^[1]

作者单位： Department of Pulmonary Medicine, University of Groningen, University Medical Center Groningen, HPC AA11, Postbus 30.001, 9700RB, Groningen, The Netherlands. ^[1] Department of Pulmonary Medicine, University of Groningen, University Medical Center Groningen, HPC AA11, Postbus 30.001, 9700RB, Groningen, The Netherlands. M.B.Muntinghe@umcg.nl. ^[2] Department of Pathology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands. ^[3] Department of Thoracic Oncology, Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands. ^[4] Department of Respiratory Medicine, Maastricht University Medical Centre, GROW Research Institute for Oncology and Reproduction, Maastricht, The Netherlands. ^[5] Department of Pulmonary Diseases, Radboud University Medical Center, Nijmegen, The Netherlands. ^[6] Department of Pulmonology, Amphia Hospital, Breda, The Netherlands. ^[7] Department of Pulmonary Diseases, Amsterdam UMC, location VU University Medical Center, Amsterdam, The Netherlands. ^[8]